• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks

    Eternity Healthcare Moves to Next Stage Regulatory Approval Phase with Lenis®

    Chelsea Pratt
    Dec. 13, 2016 07:51AM PST
    Medical Device Investing

    Eternity Healthcare is pleased to announce completion of its Lenis®, Needle-Free Injection development phase.

    Eternity Healthcare Inc. (OTC:ETAH), is pleased to announce completion of its Lenis®, Needle-Free Injection development phase. “This is a significant milestone for our company as it now means we can proceed towards regulatory approval,” said Hassan Salari, President & CEO. “The device surpassed all original design goals and with proven reliability during testing.”
    The Lenis® injector underwent rigorous testing, exceeding 1000 individual tests, proving not only reliable but economical.  The Lenis® Needle-Free Injection system has four major components that each will require individual testing to satisfy regulatory approval. The main component of the system is the injector which uses a high powered spring loaded bursting mechanism.“We believe Lenis® will revolutionize medical injections as they can now be done without patient fear of needles and with a substantial reduction in cost per injection. The injection systems market is currently estimated at $9.8 Billion for 2016 and expected to grow at 15.5% until reaching $20.17 Billion in size by 2021. Unlike our competition, our design allows for delivery of larger doses, meaning Lenis® could be used with traditional needle and syringes used worldwide. We’re confident we have a disruptive technology,” said Hassan Salari.Needle-Free Injection System Applications
    The needle-Free Injection system can be used for a vast variety of injectable medications, and supplements. These include injection of Insulin for diabetes, injection of vaccines such as flu vaccine and many others, injection of steroids, vitamins, human growth hormones, infertility medications and a vast number of cancer drugs. Further applications such as injection of epinephrine might replace Auto-Injectors such as Mylan’s Epipen®.Benefits of Needle-Free Injection System
    The Needle-Free injection system has many advantages over the existing needle injection. These include being environmentally friendly and reducing the risk of accidental poking and cross contamination. Further, the Needle-Free Injection device is good for children and people with needle phobia. It is easy to discard the used syringes as well as to recycle them.About Eternity Healthcare
    Eternity Healthcare or the “Company” (OTC:ETAH) is a healthcare company with technologies in medical devices. Our most advanced product is a Needle-Free Injection system known as Lenis®.  Our products are targeted for use by the healthcare professionals, physicians and consumers directly. More information on Eternity Healthcare, visit the Company’s website; www.eternityhealthcare.comSocial Networks:
    Twitter.com/EternityHealth
    Facebook.com/EternityHealthcare
    Safe Harbor Statement
    This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ETAH or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.Company Contact:
    Dr. Hassan Salari
    President & CEO
    (604) 324 -1113
    hassansalari@eternityhealthcare.com
    info@eternityhealthcare.com

    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Stethoscope connected to a phone with medical data overlay.

    Top 5 Small-cap Medical Device Stocks (Updated January 2025)

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×